Predictors of favourable outcome in inflammatory Crohn's disease. A retrospective observational study

Gastroenterologia y Hepatologia

Volumn 36, Issue 10, 2013, Pages 616-623

  Zabana, Yamile ^a,d   Garcia Planella, Esther ^b   van Domselaar, Manuel ^c   Mañosa, Míriam ^a,d   Gordillo, Jordi ^b   López Sanromán, Antonio ^c   Cabré, Eduard ^a,d   Domènech, Eugeni ^a,d  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Crohn's disease; Disease course; Outcome; Predictive factors

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL FEATURE; CROHN DISEASE; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SMOKING HABIT; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; CROHN DISEASE; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84889563239     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2013.07.004     Document Type: Article

References (31)

1. Ramadas A., Gunesh S., Thomas G., Williams G.T., Hawthorne A.B. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010, 59:1200-1206.
2. Peyrin-Biroulet L., Loftus E., Colombel J., Sandborn W. Early Crohn disease: a proposed definition for use in disease-modification trials. Gut 2010, 59:141-147.
3. Baert F., Moortgat L., van Assche G., Caenepeel P., Vergauwe P., De Vos M., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468.
4. Markowitz J., Grancher K., Kohn N., Lesser M., Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000, 119:895-902.
5. Sahmoud T., Hoctin-Boes G., Modigliani R., et al. Identifying patients with a high risk of relapse in quiescent Crohn's disease. Gut 1995, 37:811-818. on behalf of the GETAID group.
6. Greenstein A., Lachman P., Sachar D., et al. Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut 1998, 29:588-592.
7. Cosnes J., Cattan S., Blain A., et al. Long-term evolution of disease behaviour of Crohn's disease. Inflamm Bowel Dis 2002, 8:244-250.
8. Allez M., Lemann M., Bonnet J., Cattan P., Jian R., Modigliani R. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002, 97:947-953.
9. Louis E., Michel V., Hugot J., et al. Early development of structuring or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 2003, 52:552-557.
10. Lichtenstein G., Olson A., Travers S., et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol 2006, 101:1030-1038.
11. Beaugerie L., Seksik P., Nion-Larmurier I., Gendre J., Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006, 130:650-656.
12. Wolters F., Russel M., Sijbrandij J., on behalf of the European Collaborative Study Group on Inflammatory Bowel Disease (EC-IBD), et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006, 55:1124-1130.
13. Loly C., Belaiche J., Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008, 43:948-954.
14. Romberg-Camps M., Dagnelie P., Kester A., et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 2009, 104:371-383.
15. Lakatos P., Czegledi Z., Szamosi T., et al. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behaviour change in patients with Crohn's disease. World J Gastroenterol 2009, 15:3504-3510.
16. Rieder F., Schleder S., Wolf A., et al. Serum anti-glycan antibodies predict complicated Crohn's disease behaviour: a cohort study. Inflamm Bowel Dis 2010, 16:1367-1375.
17. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989, 24(Suppl 170):2-6.
18. Silverberg M.S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19(Suppl A):5-36.
19. Dignass A., van Assche G., Lindsay J.O., et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010, 4:28-62.
20. Sutherland L.R., Ramcharan S., Bryant H., Fick G. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology 1990, 98:1123-1128.
21. Kandiel A., Fraser A., Korelitz Brensinger C., Lewis J. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54:1121-1125.
22. Colombel J., Loftus E., Tremaine W., et al. The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients. Gastroenterology 2004, 126:19-31.
23. Dotan I. Disease behavior in adult patients: are there predictors for stricture or fistula formation. Dig Dis 2009, 27:205-210.
24. Tavarela F., Ferreiro J., Barros L., Almeida S. Clinical outcome of Crohn's disease: analysis according to the Vienna classification and clinical activity. Inflamm Bowel Dis 2001, 7:306-313.
25. Odes S., Vardi J., Friger M., on behalf of the European Collaborative Study Group on Inflammatory Bowel Disease, et al. Effect of phenotype on health care costs in Crohn's disease: A European study using the Montreal classification. J Crohns Colitis 2007, 1:87-96.
26. Munkholm P., Langholz E., Davidsen M., Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995, 30:699-706.
27. Vasiliauskas E., Plevy S., Landers C., et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology 1996, 110:1810-1819.
28. Vasiliauskas E., Kam L., Karp L., Gaiennie J., Yang H., Targan S. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000, 47:487-496.
29. Ferrante M., Henckaerts L., Joossens M., et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007, 56:1394-1403.
30. Lichtenstein G., Targan S., Dubinsky M., et al. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behaviour. Inflamm Bowel Dis 2011, 17:2488-2496.
31. Dotan I., Fisham S., Dgani Y., et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology 2006, 131:366-378.